Series D · Biotech · Cambridge, United Kingdom · Founded 2016 · 120–120 employees
Artios is a leading DNA Damage Response company developing first-in-class cancer treatments that exploit DDR pathways to selectively kill cancer cells. The company has advanced clinical-stage candidates including ATR inhibitor alnodesertib and DNA Polymerase theta inhibitor ART6043, with promising Phase 2 data showing 50% response rates in ATM-negative patients. Artios has strategic partnerships with Merck KGaA and Novartis worth up to $2.1 billion in potential milestones, and recently raised $115 million in Series D funding to accelerate registration pathways for multiple cancer indications including pancreatic, colorectal, and breast cancers.
No open roles listed right now.